Tweedy Browne Co. Vertex Pharmaceuticals Inc Transaction History

Tweedy, Browne CO LLC

$1.11 Billion
Q3 2025

A detailed history of Tweedy Browne Co. (Tweedy, Browne CO LLC) transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Tweedy, Browne CO LLC holds 39,065 shares of VRTX stock, worth $17 Million. This represents 1.38% of its overall portfolio holdings.

Number of Shares

39,065

Previous 37,253 4.86%

Holding current value

$17 Million

Previous $16.6 Million 7.75%

% of portfolio

1.38%

Previous 1.64%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 20, 2025	BUY	$366.54 - $479.53 $664,170 - $868,908	1,812 Added 4.86%	39,065 $15.3 Million
Q2 2025 Jul 29, 2025	SELL	$421.16 - $509.5 $447,693 - $541,598	-1,063 Reduced 2.77%	37,253 $16.6 Million
Q1 2025 May 15, 2025	SELL	$402.49 - $513.76 $931,764 - $1.19 Million	-2,315 Reduced 5.7%	38,316 $18.6 Million
Q4 2024 Feb 12, 2025	SELL	$396.64 - $516.74 $5.14 Million - $6.7 Million	-12,969 Reduced 24.2%	40,631 $16.4 Million
Q3 2024 Nov 13, 2024	SELL	$460.0 - $505.78 $343,160 - $377,311	-746 Reduced 1.37%	53,600 $24.9 Million
Q2 2024 Aug 12, 2024	SELL	$392.81 - $485.53 $4.85 Million - $6 Million	-12,353 Reduced 18.52%	54,346 $25.5 Million
Q1 2024 May 06, 2024	SELL	$407.69 - $446.08 $26,499 - $28,995	-65 Reduced 0.1%	66,699 $27.9 Million
Q4 2023 Feb 13, 2024	SELL	$343.0 - $410.68 $2.83 Million - $3.38 Million	-8,240 Reduced 10.99%	66,764 $27.2 Million
Q3 2023 Nov 13, 2023	BUY	$338.18 - $362.46 $25.4 Million - $27.2 Million	75,004 New	75,004 $26.1 Million

Others Institutions Holding VRTX

# of Institutions

1,791

Shares Held

231M

Call Options Held

1.84M

Put Options Held

1.21M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $111B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track Tweedy Browne Co.'s Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tweedy, Browne CO LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tweedy, Browne CO LLC and Tweedy Browne Co. with notifications on news.

Account